Utility of <sup>18</sup>F-Fluciclovine PET/CT for Detecting Prostate Cancer Recurrence in Patients With Low (< 1 ng/mL) or Very Low (< 0.3 ng/mL) Prostate-Specific Antigen Levels.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32569513.
- Also identified by DOI 10.2214/AJR.19.22180.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>OBJECTIVE.</b> We reviewed a retrospective series of 126 <sup>18</sup>F-fluciclovine PET/CT studies of patients with biochemically recurrent prostate cancer at low (< 1 ng/mL) and very low (< 0.3 ng/mL) prostate-specific antigen (PSA) levels. <b>CONCLUSION.</b> The rate of PET/CT positivity was 33% (15/46) in patients with low PSA levels and 0% (0/17) in patients with very low PSA levels. Our results suggest that <sup>18</sup>F-fluciclovine PET/CT can be helpful for localizing recurrence in patients with PSA levels between 0.3 and 1 ng/mL and that <sup>18</sup>F-fluciclovine PET/CT is not recommended in patients with PSA levels less than 0.3 ng/mL.
Medical subject headings
- Carboxylic Acids
- Cyclobutanes
- Neoplasm Recurrence, Local
- Positron Emission Tomography Computed Tomography
- Prostatic Neoplasms
- Radiopharmaceuticals